Suberanilohydroxamic acid (SAHA), a HDAC inhibitor, suppresses the effect of Treg cells by targeting the c-Myc/CCL1 pathway in glioma stem cells and improves PD-L1 blockade therapy
ConclusionSAHA inhibited the binding of c-Myc with the CCL1 promoter and then suppressed the transcription of CCL1.Additionally, it effectively blocked the interplay of CCL1-CCR8, resulting in reduced activity of Tregs and alleviation of tumor immunosuppression.
Source: Journal of Neuro-Oncology - Category: Cancer & Oncology Source Type: research
More News: Brain | Brain Tumor | Cancer | Cancer & Oncology | Glioma | Immunotherapy | Neurology | Stem Cell Therapy | Stem Cells | Study